← FDA DRUG APPROVALS

FDA ANDA · ANDA075841

PAMIDRONATE DISODIUM

Sponsor: HOSPIRA

APPLICATION
ANDA075841
TYPE
ANDA
ORIGINAL APPROVAL
2002-06-27
LATEST ACTION
2020-01-07
ROUTE
INTRAVENOUS, INJECTION
DOSAGE FORM
INJECTABLE
MARKETING STATUS
Prescription

Products

PAMIDRONATE DISODIUMPrescription
PAMIDRONATE DISODIUM 90MG/10ML (9MG/ML) · INJECTABLE · INJECTION
PAMIDRONATE DISODIUMPrescription
PAMIDRONATE DISODIUM 30MG/10ML (3MG/ML) · INJECTABLE · INJECTION
PAMIDRONATE DISODIUMPrescription
PAMIDRONATE DISODIUM 60MG/10ML (6MG/ML) · INJECTABLE · INJECTION

Approval history

2020-01-07Labeling · Supplement 19 · standardAP
2009-07-15Labeling · Supplement 16AP
2008-07-09Labeling · Supplement 14AP
2007-01-19Labeling · Supplement 10AP
2006-07-14Labeling · Supplement 9AP
2006-05-19Labeling · Supplement 7AP
2005-01-21Labeling · Supplement 2AP
2002-06-27OriginalReviewAP
VIEW ON DRUGS@FDA ↗

Related on SPEQ

Pharma industryGMP disciplineFDA drug shortagesFDA enforcement & recalls

Source: FDA Drugs@FDA. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data, not medical, legal, or regulatory advice.

Weekly Briefing

Get the Weekly GxP Briefing

Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.

Read a past issue →